A Study of Positive Emotions With Long COVID-19

NCT05676008 | Active Not Recruiting

• 1 other identifier: 1840049
• Study Type: interventional
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

This study is testing a new brief mindfulness practice for people suffering from long COVID-19 symptoms. People suffering from long COVID are particularly vulnerable to negative emotions, as they must also cope with the long-term uncertainty of physical and psychological stress beyond the acute infection. The goal of the study is to measure the ability of a brief mindfulness practice to promote a sense of well-being in people suffering from long COVID.

Conditions

Post-Acute COVID-19 Syndrome

Keywords

Mindfulness

Outcome Measures

Primary Outcomes (1)

• Well-being

  14 items from the Mental Health Continuum Short Form

  1 month

Secondary Outcomes (6)

• Perceived Stress

  1, 3 and 12 months

• Anxiety symptoms

  1, 3 and 12 months

• Depressive symptoms

  1, 3 and 12 months

• Physical health

  1, 3 and 12 months

• Cardiac symptoms

  1, 3 and 12 months

Study Arms (2)

Waitlist control

NO INTERVENTION

Treatment

EXPERIMENTAL

Behavioral: Microdosing of mindfulness

Interventions

Microdosing of mindfulness BEHAVIORAL

The intervention consists of two parts: 1) four structured training sessions offered as online synchronous classes, and 2) self-microdosing of mindfulness activities in everyday life.

Treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able to participate in online zoom sessions and complete online surveys for 3 months
• English speakers
• Had a mild to moderate in severity COVID-19 infection \> 3 months ago, feeling unwell, and are still experiencing in the present at least one PASC-related symptoms:
• Coughing or feeling short of breath
• Loss of smell or change in taste
• Recurrent Fever
• Body aches, headaches, chest pain, or stomach pain
• Brain fog (feeling like you can't think clearly)
• Having trouble sleeping
• Feeling very tired
• Mood changes

You may not qualify if:

• Adults that were admitted to an intensive care unit or placed on a respirator, had invasive heart (heart catheterization) or lung tests (bronchoscopy) performed.
• Prisoners

Sponsors & Collaborators

• University of California, Davis: lead

Study Sites (1)

University of California Davis

Sacramento, California, 95817, United States

Location

Related Publications (1)

• Monroy M, Amster M, Eagle J, Zerwas FK, Keltner D, Lopez JE. Awe reduces depressive symptoms and improves well-being in a randomized-controlled clinical trial. Sci Rep. 2025 May 12;15(1):16453. doi: 10.1038/s41598-025-96555-w.

  PMID: 40355653 DERIVED

MeSH Terms

Conditions

Post-Acute COVID-19 Syndrome

Condition Hierarchy (Ancestors)

COVID-19; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Post-Infectious Disorders; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Javier E Lopez, MD

  University of California, Davis

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 22, 2022
• First Posted: January 9, 2023
• Study Start: January 12, 2023
• Primary Completion: April 1, 2026
• Study Completion: April 1, 2026
• Last Updated: December 5, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)